Association between single nucleotide polymorphism of human angiotensin-converting enzyme 2 gene locus and clinical severity of COVID-19

Shaimaa A. Elbadri1*, Nermeen M. A. Abdallah1, Mona El-Shokry1, Amr Gaber2 and Mahmoud Kh. Elsayed1

Abstract

Background: Coronavirus disease 2019 (COVID-19) is a devastating pandemic-causing disease with a variable severity among populations. Genetic studies have pinpointed angiotensin-converting enzyme 2 (ACE2), a key enzyme for viral entry, for its possible linkage to the disease progression. The present study aimed to investigate the potential association between single nucleotide polymorphisms (SNPs) of human ACE2 gene with the severity and outcomes of COVID-19 for better patient management.

Methods: In this observational cross-sectional study, COVID-19 confirmed patients were classified into moderate and severe cases according to the 'Ain Shams University Hospitals Pocket Guide for COVID-19 Diagnosis.' Genetic analysis of ACE2 SNP rs2048683 was carried out using a TaqMan assay with the real-time polymerase chain reaction (PCR) technique.

Results: Among 90 confirmed COVID-19 patients, 78.9% (71/90) were classified as severe, and 21.1% (19/90) were classified as moderate. Laboratory biomarkers were significantly (P = 0.000) higher in the severe group than in the moderate group. Similarly, associated comorbidities such as hypertension were significant (P = 0.000) in the severe group, whereas asthma and deep venous thrombosis were significant in the moderate group (P = 0.007 and 0.006, respectively). Elevated serum ferritin level (odds ratio (OR) 162.589, 95% confidence interval (CI) 8.108–3260.293) and ACE2 rs2048683 genotype GG/G (OR 5.852, 95% CI 1.586–21.591) were both considered independent risk factors for severe disease.

Conclusion: The findings of the present study provide preliminary evidence of an association between ACE2 rs2048683 SNPs and COVID-19 severity in the Egyptian population, which may inform the need for targeted management.

Keywords: COVID-19, SARS-CoV-2, ACE2, SNP, Severity of COVID-19

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a human coronavirus that causes coronavirus disease 2019 (COVID-19) was declared a pandemic in March 2020 [1] and was mostly associated with respiratory symptoms. Nevertheless, extrapulmonary presentations have been documented as well [2].
Viral entry into the cell is mediated through interaction between spike protein projections at the viral surface and angiotensin-converting enzyme 2 (ACE2). This interaction is facilitated by cellular proteases such as transmembrane protease serine 2 [3].

ACE2 is a type 1 transmembrane enzyme expressed in a wide variety of cells in the body such as corneal, intestinal, and respiratory tract cells. It has been long known for its role in the renin-angiotensin pathway. ACE2 is considered to have a cardio-pulmonary protective effects due to its role in controlling the metabolism of angiotensin II and, to a lesser extent, angiotensin I by increasing vasodilator angiotensin 1–7 and decreasing angiotensin II levels [4]. Downregulation of ACE2 by endocytosis after viral entry releases ACE and angiotensin II leading to increased vascular permeability and subsequent lung injury [5].

The role of ACE2 in the pathogenesis of COVID-19 is complex; the overall picture of COVID-19 progression is the result of the interaction of multifactorial aspects such as ACE2 expression site, level of expression and virus binding affinity [6]. Given that the ACE2 gene is X linked (locus Xp22.2), males are hemizygous for the gene [7]. Variations in the ACE2 gene may affect the receptor structure, resulting in modulating the affinity to the virus, or disrupt the proteolytic cleavage of ACE2, thereby affecting the level of soluble ACE2, or the non-coding sequence of ACE2 [8]. The majority of ACE2 single nucleotide polymorphisms (SNPs) are introns, which do not affect the receptor protein structure but do affect its expression level [9].

ACE2 expression in lung epithelial cells increases over time after SARS-CoV-2 infection and remains at a high level for 48 h post-infection, showing that the role of ACE2 is not related only to susceptibility to infection, but also to post-infection regulation and immune response to this virus [10].

Since the start of the pandemic, researchers have been searching for a possible explanation for the variation in susceptibility to infection, disease course, and vulnerability among SARS-CoV-2-infected patients. Old age and associated comorbidities were thought to be important risk factors. However, similar disease deterioration was experienced among healthy and young groups [11]. Blood group, gender, race, ethnicity, viral load, and environmental factors were also linked to the variation in host responses. Additionally, genetic factors affecting SARS-CoV-2 entry and immune response have been investigated for possible associations [11, 12].

Cardiovascular and metabolic disorders are potentially associated with the rs2048683 SNP [13] [14]. Similar linkages between the same SNP with COVID-19 severity and the need for hospitalization have been studied in 61 Caucasian COVID-19 patients by Wooster and colleagues [15].

The above-mentioned SNP is considered an intronic variation in chrX:15590376 (GRCh38.p13), located between exon 14 and 15 of the ACE2 gene. Its global alternative allele frequency is $G = 0.638852$ (96251/266514, ALFA Project) and its frequency in African populations is $G = 0.7731$. The highest alternative allele frequency was identified in East Asian populations, while the lowest frequency was identified in European populations [16].

To our knowledge, this study is the first to investigate the rs2048683 SNP and its association with severity and outcomes among Egyptian COVID-19 patients. This could help researchers to better understand genetic predisposition to SARS-CoV-2 infection to identify patients at risk and determine the best treatment options.

Patients and methods
This observational cross-sectional study was conducted on 90 clinically and PCR confirmed-COVID-19 patients admitted to the isolation ward of Ain Shams University (ASU) Hospital between October 2020 and March 2021. This study was approved by the Ethical Committee of the Faculty of Medicine at Ain Shams University (FMA SU M D 237/2020). Informed consent was obtained from each patient or patient’s next of kin.

Data collection
Data were collected from medical records and included: sociodemographic data, clinical presentation on admission, and laboratory and radiological findings.

Classification of admitted patients
Based on clinical, laboratory and radiological findings, admitted patients were classified into mild, moderate, and severe cases according to the “Ain Shams University Hospitals Pocket Guide for COVID-19 Diagnosis” (Table 1, Additional file 1).

Molecular detection of the rs2048683 SNP
Ethlenediaminetetraacetic acid (EDTA)-anticoagulated 3 ml blood samples were collected under complete aseptic conditions from each participant and were stored at -80°C till real-time PCR processing.

Human DNA isolation and purification were performed with Thermo Scientific™ Gene JET Whole Blood Genomic DNA Purification Mini Kits #K0781 (Thermo Scientific, USA) according to manufacturer guidelines. Briefly, proteinase K and lysis solution were added to whole blood samples in a sterile microcentrifuge tube, then incubated and mixed with ethanol thoroughly. The prepared mixture was transferred to the Gene JET™ spin
column and centrifuged for 1 min at 6000 × g. Then washing was done in 2 steps using washing buffer followed by centrifugation. After that, elution buffer was added to the column membrane to elute genomic DNA.

The region flanking the rs2048683 SNP was amplified using sequence-specific primers to detect target SNP with two allele-specific TaqMan® Minor groove binder probes. One probe was labeled with fluorescein amide (FAM) dye that detected the T allele and the other probe was labeled with Victoria (VIC) dye that detected the G sequence allele. The context sequence was [VIC/FAM] TGGCAGTGTAGATATCTTTATGAAAG(T/G)GTTTAAT TCCATCTAATTTAGTATA. The 25 μL reaction mixture contained: the TaqMan Genotyping Master Mix (Catalog number: 4371353, Applied Biosystems, USA) and 5´nuclease Predesigned TaqMan® SNP Genotyping Assay (Catalog number: 4351379, Applied Biosystems, USA) was mixed with 20 ng of DNA. Real-time PCR was performed according to the manufacturer’s protocols as follows: hold cycle at 95 °C for 10 min, 45 cycles (at 95 °C for 15 s for denaturation and at 60 °C for 1 min for primer annealing/extension).

SNP analysis and allelic discrimination were automatically obtained from Rotor-Gene Q software version 2.3.3.5.

Univariate logistic regression analyses were used to test the effect of unevenly distributed variables in the two groups on the severity of the disease. Multivariate logistic regression analysis was used for the resulted significant data to determine the independent factors associated with disease severity.

Results

The majority (71.1%, 64/90) of the patients enrolled in this study were male. Participants’ ages ranged from 19 to 91 years, and the mean age was 61.57 years (± 13.55 SDs). Most (85.5%, 77/90) participants resided in Cairo governorate and the remaining resided in Giza and Qalyoubia governorates (7.25% each). Most (78.9%, 71/90) of the patients were categorized as severe cases, while (21.1%, 19/90) were categorized as moderate cases according to the ASU pocket guide. No statistically significant difference was identified between the moderate and severe groups.

Regarding the associated comorbidities, hypertension was significant (P = 0.000) in the severe group, whereas asthma and deep venous thrombosis (DVT) were significant in the moderate group (P = 0.007 and 0.006, respectively) (Fig. 1).

Lymphopenia was significant among patients in the severe group (88.7%, 63/71) compared to (52.6%, 10/19) in the moderate group (P = 0.000). Levels of C-reactive protein (CRP), serum ferritin, d-dimer, serum creatinine, and liver enzymes were significantly elevated in the severe group compared to the moderate group (P = 0.000) (Additional file 2: Table S1).

The classification of patients’ outcomes highlighted that the majority (88.9%, 80/90) of enrolled patients improved. According to the patients’ groups, all 19 moderate cases recovered completely and were discharged, and (85.9%, 61/71) of severe cases showed improvement. In contrast, (14.1%, 10/71) of patients with severe disease passed away.
Genotype and allele frequencies of the ACE2 SNP

rs2048683 genotypes and allele frequencies (major G allele and minor T allele frequencies) were assessed in relation to disease severity, associated comorbidities, and outcome of the patients.

The GG/G genotypes were significantly more prevalent in the severe group (78.9%, 56/71), whereas TT/T genotypes were more prevalent in the moderate group (57.9%, 11/19) (Table 2).

Regarding allelic assessment, out of 116 alleles, the G allele was the major (70.7%, 82/116) allele detected among all patients compared to the T allele, which was detected among (29.3%, 34/116) of patients.

A statistically significant difference was found between allelic frequencies and disease severity. Out of 92 alleles in the severe group, the G allele was detected in (80.4%, 74/92), which was significantly more than the T allele. In contrast, out of 24 alleles in the moderate group, the T allele was detected in (66.7%, 16/24) and was significantly more than the G allele ($P = 0.000$) (Table 2).

There was a significant difference between the studied gene alleles and disease outcome, with all deceased patients having the G allele ($P = 0.025$) (Fig. 2).

Univariate logistic regression analysis was performed on variables that were unequally distributed among the different groups to connect them with the disease severity. Then multivariate logistic regression analysis was done revealed that both elevated serum ferritin levels (OR 162.589, 95% CI 8.108–3260.293) and ACE2 rs2048683 genotypes GG/G (OR 5.852, 95% CI 1.586–21.591) were independently associated with disease severity (Additional file 2: Table S2a, b).

Discussion

This study confirms the association of ACE2 SNPs and epigenetic factors with the severity of SARS-COV-2 infection. Male predominance (71%) in the study can be attributed to associated risk factors that are culturally linked to males, such as smoking [17]. Furthermore, females have stronger immune responses than
Table 2  Genotype distribution and allele frequencies of rs2048683 among the studied patients and their associations with clinical diseases

| Gene allele* | All patients n = 90 F:26, M:64 | Moderate n = 19 F:5, M:14 | Severe n = 71 F:21, M:50 | P-value* | Hypertension n = 70 | Non hypertensive n = 40 | CVD n = 40 | P-value* | DM n = 22 | P-value* |
|--------------|--------------------------------|-------------------------|-------------------------|----------|---------------------|------------------------|----------|----------|-----------|----------|
| G            | 82 (70.7%)                     | 8 (33.3%)               | 74 (80.4%)              | **0.000** | 73 (79.3%)          | 9 (37.5%)              | **0.000** | 33 (70.2%) | 49 (71.0%) | 0.924    | 22 (81.5%) | 60 (67.4%) | 0.160    |
| T            | 34 (29.3%)                     | 16 (66.7%)              | 18 (19.6%)              |           | 19 (20.7%)          | 15 (62.5%)             |          | 14 (29.8%) | 20 (29.0%) |          | 5 (18.5%) | 29 (32.6%) |          |
| rs2048683 genotype |                       |                        |                         | **0.000** | 53 (75.7%)          | 6 (30.0%)              | **0.001** | 28 (70.0%) | 31 (62.0%) | **0.047** | 17 (77.3%) | 42 (61.8%) | **0.282** |
| GG/G         | 59 (65.6%)                     | 3 (15.8%)               | 56 (78.9%)              |           | 16 (22.9%)          | 0 (0.0%)               | **0.021** | 5 (12.5%) | 11 (22.0%) | **0.077** | 3 (13.6%) | 13 (19.1%) | **0.574** |
| GT           | 7 (7.8%)                       | 5 (26.3%)               | 2 (2.8%)                |           | 4 (5.7%)            | 3 (15.0%)              |          | 0 (0.0%)  | 7 (14.0%)  |          | 2 (9.1%)  | 5 (7.4%)   |          |
| TT/T         | 24 (26.7%)                     | 11 (57.9%)              | 13 (18.3%)              |           | 13 (18.6%)          | 11 (55.0%)             |          | 12 (30.0%) | 12 (24.0%) |          | 3 (13.6%) | 21 (30.9%) |          |
| rs2048683 genotype in females |                       |                        |                         | **0.000** | 16 (22.9%)          | 0 (0.0%)               | **0.021** | 5 (12.5%) | 11 (22.0%) | **0.077** | 3 (13.6%) | 13 (19.1%) | **0.574** |
| GG           | 16 (17.8%)                     | 0 (0.0%)                | 16 (22.5%)              |           | 16 (22.9%)          | 0 (0.0%)               | **0.053** | 5 (12.5%) | 11 (22.0%) |          | 2 (9.1%)  | 5 (7.4%)   |          |
| GT           | 7 (7.8%)                       | 5 (26.3%)               | 2 (2.8%)                |           | 4 (5.7%)            | 3 (15.0%)              |          | 0 (0.0%)  | 7 (14.0%)  |          | 2 (9.1%)  | 5 (7.4%)   |          |
| TT           | 3 (3.3%)                       | 0 (0.0%)                | 3 (4.2%)                |           | 2 (2.9%)            | 1 (5.0%)               |          | 2 (5.0%)  | 1 (2.0%)   |          | 0 (0.0%)  | 3 (4.4%)   |          |
| rs2048683 genotype in males |                       |                        |                         | **0.000** | 37 (52.9%)          | 6 (30.0%)              | **0.003** | 23 (57.5%) | 20 (50.0%) |          | 14 (63.6%) | 29 (42.6%) | **0.120** |
| G            | 43 (47.8%)                     | 3 (15.8%)               | 40 (56.3%)              |           | 37 (52.9%)          | 6 (30.0%)              | **0.003** | 23 (57.5%) | 20 (50.0%) |          | 14 (63.6%) | 29 (42.6%) | **0.120** |
| T            | 21 (23.3%)                     | 11 (57.9%)              | 10 (141%)               |           | 11 (15.7%)          | 10 (50.0%)             |          | 10 (25.0%) | 11 (22.0%) |          | 3 (13.6%) | 18 (26.5%) |          |

G allele: male G, female GG + GT; T allele: male T, female TT + GT
Bold indicates significance
*Chi-square test; the G allele is represented twice among females and only once among males, therefore, the total count of G alleles among all patients is 116, calculated as follows: (5 × 2 + 14) + (21 × 2 + 50) in the severe and moderate groups, respectively
males, either because of direct effects of sex hormones or an underlying discrepancy in the expression of genes encoded on the X and Y chromosomes [17, 18].

We identified that patients in the severe group had significantly higher levels of laboratory biomarkers (CRP, serum ferritin, and D-dimer) compared to patients in the moderate group. This finding is consistent with that reported in other studies [19, 20]. Given that, elevated biomarkers can predict respiratory deterioration; they are currently considered markers of poor outcome for COVID-19 patients and caused by associated systemic hyperinflammatory reactions [21]. A significant finding of lymphopenia observed among patients was similar to findings in previous studies [10, 19] and can be explained by a direct result of viral invasion or distorted inflammatory cytokines leading to lymphocytes apoptosis [19, 22].

In this study, an elevated serum ferritin level was identified as the only laboratory marker that served as a significant independent risk factor for severe COVID-19. This finding comes in agreement with other studies that linked elevated serum ferritin levels to disease severity and outcome, making it a reliable parameter for predicting poor prognosis and prioritizing patients [23, 24].

Significant differences were observed between ACE2 rs2048683 SNP genotypes and allele frequencies in relation to disease severity and outcome. The proportion of the G allele (major allele) detected in (70.7%) of all patients was significantly higher in the severe group than in the moderate group ($P=0.000$). This allele frequency (AF) is comparable to that reported in the 1KGP (1000 Genomes Project) from Africa which is 0.8066 and 0.768 in International HapMap Project [16]. Additionally, our results indicate that having ACE2 rs2048983 SNP GG/G genotypes was an independent risk factor for severe COVID-19 disease (OR 5.852).

However, the rs2048683 SNP was not associated with disease severity in two cohorts of British and Chinese COVID-19 patients [25, 26]. In contrast, Martinez-Sanz et al. noticed no increase in susceptibility to SARS-CoV-2 infection associated with the rs2048683 SNP [27].

The ACE2 untranslated gene region and intron polymorphisms such as rs2048683 do not affect ACE2 amino acid and protein structure but may alter mRNA splicing and stability, affecting gene expression and protein levels. As a result, they have the potential to influence disease progression and course [28].

Another previously studied intronic ACE2 SNP, rs2285666, which is located near intron 3 and affects the splicing mechanism, has been linked to a lower infection rate and case fatality rate among Indian individuals [29]. Interestingly, the same rs2285666 SNP was significant among Egyptian patients with severe COVID-19 [30]. The differences in AFs of ACE2 gene variants between populations may explain the diverse genetic basis that alters ACE2 functions or expression, thus affecting disease severity and outcomes.

The most common comorbidity identified in the current study was hypertension (HTN). Severe cases showed more comorbidities with a significant statistical difference recorded in HTN ($P=0.000$). This is consistent with the findings of Guan et al. and Li et al. regarding COVID-19 patients in China [19] [31].

We found a significant association between rs2048683 genotypes and HTN, cardiovascular diseases ($P=0.001$ and 0.047, respectively). The G allele was significantly more frequent among hypertensive patients ($P=0.000$). Similarly, Hamet et al. showed that British COVID-19 patients with severe outcomes had a higher percentage of hypertension and diabetes than moderate patients. They investigated the association of 12 ACE2 SNPs with hypertension and discovered that the rs2048683 and rs4646156 SNPs were significantly associated with hypertension [25].

In China, the rs2048683 SNP was associated with an increased risk of developing type 2 diabetes and diabetic-related cardiovascular risk as well as an increased left ventricular mass index, which is an indicator of hypertensive cardiomyopathy [13]. Among Mexican individuals, a link was found between diastolic and systolic hypertension and the rs2048683 SNP in study participants with healthy lipid profiles [14]. Other studies, however, found no link between the rs2048683 SNP and essential hypertension, dyslipidemia, or ischemic stroke [32, 33].

The role of ACE2 variants in cardiovascular and metabolic diseases may be due to decreased ACE2 amount and expression, which increases inflammation and tissue injuries caused by unmetabolized angiotensin II and an unbalanced renin–angiotensin–aldosterone system.
Conclusion
To the best of our knowledge, this is the first study to look at the genetic link between the ACE2 SNP rs2048683 and disease severity among patients with confirmed COVID-19 in Egypt. We found a possible association between the ACE2 rs2048683 polymorphism and disease progression. Large-scale studies are needed to validate this SNP's role as a possible genetic marker for disease severity.

Limitations
The sample size used in this study was relatively small due to high costs associated with molecular testing. We were also challenged with a lack of studies that addressed similar SNPs.

Abbreviations
ACE2: Angiotensin-converting enzyme 2; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SNP: Single nucleotide polymorphisms; COVID-19: Coronavirus disease 2019; PCR: Polymerase chain reaction; OR: Odds ratio; CI: Confidence interval; HRCT: High-resolution computed tomography; ICU: Intensive care unit; BMI: Body mass index; HTN: Hypertension; CVD: Cardiovascular disease; COPD: Chronic obstructive pulmonary disease; DM: Diabetes mellitus; CKD: Chronic kidney disease; ARDs: Acute respiratory diseases; DVT: Deep venous thrombosis; EDTA: Ethylenediaminetetraacetic acid; FAM: Fluorescein amidite; VIC: Victoria; CRP: C-reactive protein.

Supplementary Information
The online version contains supplementary material available at [https://doi.org/10.1186/s40442-022-00331-b](https://doi.org/10.1186/s40442-022-00331-b).

Acknowledgements
Not applicable.

Author contributions
SE: did research, data analysis, methodological work, software application, major manuscript writing, manuscript editing. ME: did research supervision, assessment in manuscript writing, manuscript editing. AG: did blood samples and data collection. SE: did research supervision. All authors read and approved the final manuscript.

Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
This study was approved by the Ethical Committee at Faculty of Medicine Ain Shams University. Informed consent was obtained from each patient or patient’s next of kin.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Medical Microbiology and Immunology, Faculty of Medicine, Ain Shams University, Cairo, Egypt. 2 Anesthesia, Intensive Care and Pain Management, Faculty of Medicine, Ain Shams University, Cairo, Egypt.

Received: 10 May 2022 Accepted: 5 August 2022
Published online: 23 August 2022

References
1. Curtinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Biomed 91:157–160
2. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, Bikdeli B, Ahuwalia N, Ausiello JC, Wan EY, Freedberg DE, Kirtane AJ, Pankih SA, Maurer MS, Nordvig AS, Accili D, Bathon JM, Mohan S, Bauer KA, Leon MB, Krumholz HM, Unel N, Mehra MR, Ellikin MSV, Stone GW, Schwartz A, Ho DD, Bleizfian JP, Landry DW (2020) Extrapulmonary manifestations of COVID-19. Nat Med 26(7):1017–1032. https://doi.org/10.1038/s41591-020-0968-3
3. Hoffmann M, Klein-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S et al (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181(2):270–280.e8
4. Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ, Razada MK, Grant MB, Oudit GY (2020) Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system, celebrating the 20th anniversary of the discovery of ACE2. Circ Res 126(10):1456–1474. https://doi.org/10.1161/CIRCRESAHA.120.317015
5. Fu J, Zhou B, Zhang L, Baijai KS, Wei C, Liu X et al (2020) Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Mol Biol Rep 47(6):4383–4392
6. Novelli A, Biancolella M, Borgia P, Cocciaferrro D, Colonna VL, D’Apice MR et al (2020) Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Hum Genomics 14(1):1–6
7. Chen F, Zhang Y, Li X, Li W, Liu X, Xue X (2021) The Impact of ACE2 Polymorphisms on COVID-19 disease: susceptibility, severity, and therapy. Front Cell Infect Microbiol 11:753721. https://doi.org/10.3389/fcimb.2021.753721
8. Bakhshandeh B, Sorboni SG, Javanmard AR, Mottaghi SS, Mehrabi MR, Sorouri F, Abbasi A, Jahanafrooz Z (2021) Variants in ACE2; potential influences on virus infection and COVID-19 severity. Infect Genet Evol 90:104773. https://doi.org/10.1016/j.meegid.2021.104773
9. Panari A, Hosseini MM, Moballagh-Eslam M, Akhavan-Niaki H (2021) Comprehensive in silico identification of impacts of ACE2 SNPs on COVID-19 susceptibility in different populations. Gene Rep 22:100979
10. Li G, He X, Zhang L, Ran Q, Wang J, Xiong A et al (2020) Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19. J Autoimmun 112:102463
11. Geng MJ, Wang LP, Ren X, Yu JX, Chang ZR, Zheng CJ, An ZJ, Li Y, Yang XK, Zhao HT, Li ZJ, Feng ZJ (2021) Risk factors for developing severe COVID-19 in China: an analysis of disease surveillance data. Infect Dis Poverty 10(1):48. https://doi.org/10.1186/s40249-021-00820-9 (Erratum in: Infect Dis Poverty. 2021;10(1):81
12. Yildirim Z, Sahin OS, Yazar S, Bozok CV (2021) Genetic and epigenetic factors associated with increased severity of COVID-19. Cell Biol Int 45(6):1158–1174. https://doi.org/10.1002/cbin.11572
13. Liu C, Li Y, Guan T, Lai Y, Shen Y, Zeyaweeding A, Zhao H, Li F, Maimaiti T (2018) ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus. Cardiovasc Diabetol 17(1):127. https://doi.org/10.1186/s12933-018-0771-3

14. Lozano-Gonzalez K, Padilla-Rodriguez E, Texis T, Gutiérrez MN, Rodríguez-Dorantes M, Cuevas-Córdoña B et al (2020) Allele frequency of ACE2 intron variants and its association with blood pressure. DNA Cell Biol 39(11):2095–2101

15. Wooster L, Nicholson CJ, Sigurslid HH, Cardenas CLL, Malhotra R (2020) Polymorphisms in the ACE2 locus associate with severity of COVID-19 infection. medRxiv. https://doi.org/10.1101/2020.06.18.20135152

16. Sherry ST, Ward M, Sirotkin K (1999) dbSNP-database for single nucleotide polymorphisms and other classes of minor genetic variation. Genome Res 9(8):677–679

17. Arnold RH (2020) COVID-19—does this disease kill due to imbalance of the renin angiotensin system (RAS) caused by genetic and gender differences in the response to viral ACE2 attack? Heart Lung Circ 29:964–972

18. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL (2020) Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ 11(1):29

19. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li L, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang J, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CL, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382(18):1708–1720. https://doi.org/10.1056/NEJMoa2002032

20. Ragab E, Mahrous AH, el Sheikh GM (2020) COVID-19 infection: epidemiological, clinical, and radiological expression among adult population. Egypt J Radiol Nucl Med. https://doi.org/10.1186/s43055-020-00341-9

21. Huang J, Pranata R, Lim MA, Oehadian A, Alisjahbana B (2020) C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis. Therap Adv Respir Dis. https://doi.org/10.1177/1753466620937175

22. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, Wang Q, Miao H (2020) Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study. Signal Transduct Target Ther 5(1):33. https://doi.org/10.1038/s41392-020-0148-4

23. Hussein AM, Taha ZB, Gailan Malek A, Akram Rasul K, Qasim Hazim D, Jalal Ahmed R et al (2021) D-dimer and serum ferritin as an independent risk factor for severity in COVID-19 Patients. Mater Today Proc. https://doi.org/10.1016/j.matpr.2021.04.009

24. Vargas-Vargas M, Cortés-Rojo C (2020) Ferritin levels and COVID-19. Rev Panam Salud Publica 44:e72. https://doi.org/10.26633/RPSP2020.72

25. Hamet P, Pausova Z, Attaoua R, Hishmih C, Haloui M, Shin J et al (2021) SARS-CoV-2 Receptor ACE2 gene is associated with hypertension and severity of COVID 19: interaction with sex, obesity, and smoking. Am J Hypertens 34(4):367–376

26. Wang J, Zou H, Corpe C (2022) An observed association between angiotensin-converting enzyme 2 polymorphisms and COVID-19 severity in China. J Infect 84(1):e21–e22. https://doi.org/10.1016/j.jinf.2021.10.020

27. Martínez-Sanz J, Jiménez D, Martínez-Campello L, Cruz R, Vizcarra P, Sánchez-Conde M, Ron R, Rodríguez M, Herrera S, Moreno S, López-Huertas MR, Serrano-Villar S (2021) Role of ACE2 genetic polymorphisms in susceptibility to SARS-CoV-2 among highly exposed but non infected healthcare workers.Emerg Microbes Infect 10(1):493–496. https://doi.org/10.1080/22221751.2021.1902755

28. Singh H, Choudhari R, Nema V, Khan AA (2021) ACE2 and TMPRSS2 polymorphisms in various diseases with special reference to its impact on COVID-19 disease. Microb Pathog 150:104621

29. Srivastava A, Bandopadhayya A, Das D, Pandey RK, Singh V, Khanam N et al (2020) Genetic association of ACE2 rs2285666 polymorphism with COVID-19 Spatial distribution in India. Front Genet 11:564741

30. Abdelsattar S, Kasemy ZA, Ewida SF, Abo-Elsoud RA, Zytoon AA, Abdelaal GA, Abdelgawad AS, Khalil FO, Kamel HF (2022) ACE2 and TMPRSS2 SNPs as determinants of susceptibility to, and severity of, a COVID-19 infection. Bi J Biomed Sci 79:10238. https://doi.org/10.3389/bjbs.2021.10238

31. Li X, Xu S, Yu M, Wang K, Tao X, Zhou Y et al (2020) Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol 146(1):110–118

32. Luo Y, Liu C, Guan T, Li Y, Lai Y, Li F et al (2019) Association of ACE2 genetic polymorphisms with hypertension-related target organ damages in South Xinjiang. Hypertens Res 42(5):681–689

33. Pari Y, Wang T, Li Y, Guan T, Lai Y, Shen Y et al (2018) Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis 17(1):241

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.